by University of Liverpool Credit: CC0 Public Domain A new systematic review by University of Liverpool researchers highlights the positive impact that triple-combination therapy has on the wellbeing of people with Cystic Fibrosis (CF). In August 2020, the European Commission formally granted a license to Kaftrio, the first triple-combination therapy to tackle the underlying cause of...
By ANDREW JOSEPH @Drew Q Joseph Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the same as one of Vertex’s (VRTX) earlier CF treatments....
AMERICAN THORACIC SOCIETY July 2, 2018–An antioxidant-enriched vitamin may decrease respiratory exacerbations in people with cystic fibrosis(CF), according to new research published online in April in the American Journal of Respiratory and Critical Care Medicine. In “Effects of an Antioxidant-Enriched Multivitamin in Cystic Fibrosis: Randomized, Controlled, Multicenter Trial,” Scott D. Sagel, MD, PhD, a professor of pediatrics at Children’s...
Benat Broderick argued his life has been transformed since taking Orkambi Ireland’s Health Service Executive approved the use of the drug in April 2017 But UK watchdogs have denied patients access to the £100,000 medication Experts believe using the tablets could stop the illness from becoming severe A 14-year-old boy dying from cystic fibrosis today...
Orkambi helped to improve the diminishing lung function of child sufferers Charities claim the latest findings of the combination medication are exciting Cystic Fibrosis Trust said the drug has the power to ‘prevent irreversible damage’ A drug that targets the underlying cause of cystic fibrosis has been hailed as a ‘major step forward’ by experts....
